Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality.

Authors: Yano, K  Liaw, PC  Mullington, JM  Shih, SC  Okada, H  Bodyak, N  Kang, PM  Toltl, L  Belikoff, B  Buras, J  Simms, BT  Mizgerd, JP  Carmeliet, P  Karumanchi, SA  Aird, WC 
Citation: Yano K, etal., J Exp Med. 2006 Jun 12;203(6):1447-58. Epub 2006 May 15.
Pubmed: (View Article at PubMed) PMID:16702604
DOI: Full-text: DOI:10.1084/jem.20060375

Sepsis, the systemic inflammatory response to infection, is a leading cause of morbidity and mortality. The mechanisms of sepsis pathophysiology remain obscure but are likely to involve a complex interplay between mediators of the inflammatory and coagulation pathways. An improved understanding of these mechanisms should provide an important foundation for developing novel therapies. In this study, we show that sepsis is associated with a time-dependent increase in circulating levels of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in animal and human models of sepsis. Adenovirus-mediated overexpression of soluble Flt-1 (sFlt-1) in a mouse model of endotoxemia attenuated the rise in VEGF and PlGF levels and blocked the effect of endotoxemia on cardiac function, vascular permeability, and mortality. Similarly, in a cecal ligation puncture (CLP) model, adenovirus-sFlt-1 protected against cardiac dysfunction and mortality. When administered in a therapeutic regimen beginning 1 h after the onset of endotoxemia or CLP, sFlt peptide resulted in marked improvement in cardiac physiology and survival. Systemic administration of antibodies against the transmembrane receptor Flk-1 but not Flt-1 protected against sepsis mortality. Adenovirus-mediated overexpression of VEGF but not PlGF exacerbated the lipopolysaccharide-mediated toxic effects. Together, these data support a pathophysiological role for VEGF in mediating the sepsis phenotype.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 6483601
Created: 2012-05-29
Species: All species
Last Modified: 2012-05-29
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.